The Weekly Roundup

February 24, 2017 | Pamela Youngberg Dickson

Spending on Specialty drugs has nearly doubled in the past five years and has contributed to massive overall medicine spending growth. This week, Drug Channels’ Adam Fein released his analysis of the 2016 Specialty pharmacy estimates naming the largest players in the $115 billion-dollar market. He deftly points out one of the challenges felt by many independents who want to grow their own Specialty practices: many PBMs limit the ability of an independent to compete by requiring patients to use the pharmacies that the PBMs own, concentrating most of the business year-after-year with two players—ExpressScripts and CVS Health. Still, there is opportunity in Specialty, and it may well be a good way to diversify. Our own Sterling Specialty president, Tim Gallagher, had the opportunity to talk about pharmacy’s foray into the Specialty field, and spoke to a group of interested pharmacists at the NCPA Specialty Conference in New Orleans last October. Here’s the transcript, if you missed it. 

Here are few other stories that might be of interest:

Continue reading →

The Weekly Roundup

February 11, 2017 | Pamela Youngberg Dickson

There have been a lot of brand makeovers underway in pharma lately. While NCPA urges legislators to keep their eyes on the ball, PBMs have been working hard over the last few weeks to clear themselves of responsibility for drug prices by placing the blame on anyone but themselves. Check out the video on transparency in this piece from Business Insider. (Notice any stakeholders missing in their analysis?) Meanwhile, on Wall Street, analysts were looking for more guidance on the role of CVS Health’s PBM division this week, which reportedly “exceeded expectations” in the fourth quarter. CVS has also been busy with a CMS report on the role and impact of DIR fees, and the usual commentators are also weighing in on the debate. All the while, drug manufacturers are reshaping public perception to laud the importance of R&D. Have you noticed?

Here are few other stories that might be of interest:


Continue reading →